Calsed has competitive advantages over other drugs used in the second-series setting in efficacy, tolerability and safety, and delivery. Related StoriesCornell biomedical engineers develop 'super natural killer cells' to destroy tumor cells in lymph nodesMD Anderson study reveals why chemotherapy medicines not effective for most pancreatic cancer patientsStudy shows uncommon HER2 missense mutations do not spread breast cancer by themselves Calsed has already launched in Japan, and instead of Stage III trial results, Phase II data in Western populations comparing the agent with GlaxoSmithKline’s Hycamtin are encouraging and present improved efficacy data, stated Decision Assets’ Analyst Amy Duval, M.Res.NK cells mediate anti-tumor activity by multiple mechanisms. NK cells directly lyse tumor cells through the secretion of cytotoxic granules; they promote apoptosis through the creation of interferon-gamma , and they improve the anti-tumor response of additional immune cells. NK cells are activated by varied indicators, including type I interferons. Large amounts of type I IFN are made by plasmacytoid dendritic cells upon engagement of the design recognition receptor TLR7. The organic ligand for TLR7 is definitely single stranded RNA, although a number of small molecule agonists are also discovered.